Article

3,4-Methylenedioxymethamphetamine (MDMA, “Ecstasy”) Induces Fenfluramine-Like Proliferative Actions on Human Cardiac Valvular Interstitial Cells in Vitro

Department of Medicinal Chemistry, Virginia Commonwealth University, Ричмонд, Virginia, United States
Molecular Pharmacology (Impact Factor: 4.12). 07/2003; 63(6):1223-9. DOI: 10.1124/mol.63.6.1223
Source: PubMed

ABSTRACT Recent findings have implicated the 5-hydroxytryptamine 2B (5-HT2B) serotonin receptor in mediating the heart valve fibroplasia [valvular heart disease (VHD)] and primary pulmonary hypertension observed in patients taking the now-banned appetite suppressant fenfluramine (Pondimin, Redux). Via large-scale, random screening of a portion of the receptorome, we have discovered that the amphetamine derivative 3,4-methylenedioxymethamphetamine (MDMA, "Ecstasy") and its N-demethylated metabolite 3,4-methylenedioxyamphetamine (MDA) each preferentially bind to and activate human recombinant 5-HT2B receptors. We also demonstrate that MDMA and MDA, like fenfluramine and its N-deethylated metabolite norfenfluramine, elicit prolonged mitogenic responses in human valvular interstitial cells via activation of 5-HT2B receptors. We also report that pergolide and dihydroergotamine, two drugs recently demonstrated to induce VHD in humans, potently activate 5-HT2B receptors, thus validating this assay system for its ability to predict medications that might induce VHD. Our discovery that MDMA and a major metabolite, MDA, induce prolonged mitogenic responses in vitro similar to those induced by fenfluramine and norfenfluramine in vivo (i.e., valvular interstitial cell fibroplasia) predict that long-term MDMA use could lead to the development of fenfluramine-like VHD. Because of the widespread abuse of MDMA, these findings have major public health implications. These findings also underscore the necessity of screening current and future drugs at h5-HT2B receptors for agonist actions before their use in humans.

Download full-text

Full-text

Available from: Richard B Rothman, Jul 25, 2014
2 Followers
 · 
506 Views
  • Source
    • "Ki determinations, receptor binding profiles and functional assays were provided by the National Institute of Mental Health's Psychoactive Drug Screening Program essentially as previously described [12]–[16]; full methodological details are found on-line at: http://pdsp.med.unc.edu/UNC-CH%20Protocol%20Book.pdf In brief, compounds were initially screened in quadruplicate at a fixed concentration of 10 µM. "
    [Show abstract] [Hide abstract]
    ABSTRACT: In this paper we determined the pharmacological profiles of novel ketamine and phencyclidine analogues currently used as 'designer drugs' and compared them to the parent substances via the resources of the National Institute of Mental Health Psychoactive Drug Screening Program. The ketamine analogues methoxetamine ((RS)-2-(ethylamino)-2-(3-methoxyphenyl)cyclohexanone) and 3-MeO-PCE (N-ethyl-1-(3-methoxyphenyl)cyclohexanamine) and the 3- and 4-methoxy analogues of phencyclidine, (1-[1-(3-methoxyphenyl)cyclohexyl]piperidine and 1-[1-(4-methoxyphenyl)cyclohexyl]piperidine), were all high affinity ligands for the PCP-site on the glutamate NMDA receptor. In addition methoxetamine and PCP and its analogues displayed appreciable affinities for the serotonin transporter, whilst the PCP analogues exhibited high affinities for sigma receptors. Antagonism of the NMDA receptor is thought to be the key pharmacological feature underlying the actions of dissociative anaesthetics. The novel ketamine and PCP analogues had significant affinities for the NMDA receptor in radioligand binding assays, which may explain their psychotomimetic effects in human users. Additional actions on other targets could be important for delineating side-effects.
    PLoS ONE 03/2013; 8(3):e59334. DOI:10.1371/journal.pone.0059334 · 3.23 Impact Factor
  • Source
    • "In the 1980s it was determined that retroperitoneal fibrosis caused by the ergot methysergide is due to the metabolism of this compound into methylergonovine which converts it from a 5-HT 2B receptor antagonist to agonist [25]. Subsequently agonism of 5-HT 2B has been implicated in fibrosis caused by fenfluramine used in the treatment of obesity [26] and psychiatric disorders [27] and the hallucinogen MDMA [28], both of which trigger 5-HT 2B signaling. Dopamine agonists with structural similarity to 5-HT such as pergolide and cabergoline that are used in the treatment of Parkinson's disease have also been associated with development of fibrosis in heart valves involving 5-HT 2B agonism, thus limiting their clinical utility [29]. "
    [Show abstract] [Hide abstract]
    ABSTRACT: The molecule serotonin (5-hydroxytryptamine or 5-HT) is involved in numerous biological processes both inside and outside of the central nervous system. 5-HT signals through 5-HT receptors and it is the diversity of these receptors and their subtypes that give rise to the varied physiological responses. It is clear that platelet derived serotonin is critical for normal wound healing in multiple organs including, liver, lung heart and skin. 5-HT stimulates both vasoconstriction and vasodilation, influences inflammatory responses and promotes formation of a temporary scar which acts as a scaffold for normal tissue to be restored. However, in situations of chronic injury or damage 5-HT signaling can have deleterious effects and promote aberrant wound healing resulting in tissue fibrosis and impaired organ regeneration. This review highlights the diverse actions of serotonin signaling in the pathogenesis of fibrotic disease and explores how modulating the activity of specific 5-HT receptors, in particular the 5-HT2 subclass could have the potential to limit fibrosis and restore tissue regeneration. This article is part of a Special Issue entitled: Fibrosis: Translation of basic research to human disease.
    Biochimica et Biophysica Acta 09/2012; 1832(7). DOI:10.1016/j.bbadis.2012.09.009 · 4.66 Impact Factor
  • Source
    • "Activation of 5-HT 2B receptors in some cell types has also been shown to stimulate nitric oxide synthase (Manivet et al., 2000). In fibroblasts and smooth muscle cells, the biological result of activating 5-HT 2B receptors is mitosis (Fitzgerald et al., 2000; Nebigil et al., 2000a, 2000b; Setola et al., 2003) and secretion of inflammatory cytokines and extracellular matrix (ECM) components (Hafizi et al., 2000; Jaffre et al., 2009). As such, 5-HT 2B receptors appear to play a crucial role in allowing these cells to maintain the structural homeostasis of the tissues comprising them (e.g., myocardium, heart valves, and blood vessels). "
    [Show abstract] [Hide abstract]
    ABSTRACT: Carcinoid heart disease was one of the first valvular pathologies studied in molecular detail, and early research identified serotonin produced by oncogenic enterochromaffin cells as the likely culprit in causing changes in heart valve tissue. Researchers and physicians in the mid-1960s noted a connection between the use of several ergot-derived medications with structures similar to serotonin and the development of heart valve pathologies similar to those observed in carcinoid patients. The exact serotonergic target that mediated valvular pathogenesis remained a mystery for many years until similar cases were reported in patients using the popular diet drug Fen-Phen in the late 1990s. The Fen-Phen episode sparked renewed interest in serotonin-mediated valve disease, and studies led to the identification of the 5-HT(2B) receptor as the likely molecular target leading to heart valve tissue fibrosis. Subsequent studies have identified numerous other activators of the 5-HT(2B) receptor, and consequently, the use of many of these molecules has been linked to heart valve disease. Herein, we: review the molecular properties of the 5-HT(2B) receptor including factors that differentiate the 5-HT(2B) receptor from other 5-HT receptor subtypes, discuss the studies that led to the identification of the 5-HT(2B) receptor as the mediator of heart valve disease, present current efforts to identify potential valvulopathogens by screening for 5-HT(2B) receptor activity, and speculate on potential therapeutic benefits of 5-HT(2B) receptor targeting.
    Pharmacology [?] Therapeutics 03/2011; 132(2):146-57. DOI:10.1016/j.pharmthera.2011.03.008 · 7.75 Impact Factor
Show more